Analytical Data
-
Gene name
OX40/TNFRSF4/CD134
- Application
-
Alternative Names
CD134; TNFRSF4; ACT35; OX40; TXGP1L; TAX transcriptionally-activated glycoprotein 1 receptor
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P47741
-
Expression Region
Lys29~Gly210
-
Molecular Weight
21kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The OX40 protein, also known as TNFRSF4 or CD134, is a member of the tumor necrosis factor receptor superfamily and plays a pivotal role in regulating immune responses. It is predominantly expressed on activated T cells and serves as a co-stimulatory molecule that enhances T cell proliferation, survival, and cytokine production when engaged by its ligand, OX40L. Research has shown that OX40 signaling is crucial for the development of effective adaptive immune responses and has implications in both enhancing anti-tumor immunity and modulating autoimmune disorders. The study of OX40 has gained significant attention in the context of cancer immunotherapy, where its activation can potentiate the efficacy of existing therapies by boosting T cell activity against tumors. Additionally, its role in maintaining T cell memory suggests potential benefits in vaccine development. As such, the generation of recombinant OX40 proteins is critical for characterizing its biological functions, understanding the intricacies of OX40/OX40L interactions, and exploring therapeutic applications, including the development of OX40-targeted monoclonal antibodies. Researchers are particularly interested in elucidating the mechanistic pathways that govern OX40's effects on T cell dynamics and its potential to modulate the immune landscape in various diseases, paving the way for innovative therapeutic strategies.
